30 results about "Molecular phenotype" patented technology

Disclosed are platforms, systems, media, and methods for enabling a clinical trial administrator to identify individuals potentially eligible for a clinical trial based at least in part on an individual molecular phenotype, review profiles of identified individuals, and make clinical trial enrollment offers to identified individuals. Also disclosed are platforms, systems, media, and methods for enabling a patient to review and accept or decline clinical trial enrollment offers and identify relevant individuals, clinical trials, and therapies based at least in part on an individual molecular phenotype.

The invention relates to the technical field of biomedical engineering and particularly relates to a long-term in-vitro culture and directional differentiation system and method for a liver stem cell. The long-term in-vitro culture and directional differentiation system comprises an amplification culture medium with specific chemical components, and a differential medium with specific chemical components, wherein the amplification culture medium is used for carrying out in-vitro culture of a mouse or human liver stem cell, and the differential medium is used for carrying out induced differentiation on the mouse or human liver stem cell to form a matured liver cell. By using the long-term in-vitro culture and directional differentiation system and method, a selectively-amplified liver stem cell in mother cells of the liver can be obtained from a mouse embryonic liver tissue or through human multipotential stem cell differentiation, the liver stem cell can be cultured for more than 20 generations under such a condition, and the stable molecular phenotype of the liver stem cell is maintained. By using the long-term in-vitro culture and directional differentiation system and method, the cultured mouse or human liver stem cell can be further subjected to induced differentiation to form the matured liver cell with functions of secreting albumin, metabolizing urea and the like.

The invention discloses an imaging device and a method for quickly acquiring 3D structure information and molecular phenotype information of a large sample. The device comprises a sample storage device, a 3D mobile station used for driving the sample storage device to move in a 3D space, a vibration slicing module used for slicing a sample to get the shallow part of the sample, and a wide-field optical microscopic imaging module used for performing high-throughput tomography imaging on the shallow part of the sample. The defects in the prior art, for example, the sample preparation process is complex, the sample shape and fluorescence signals are affected, and imaging is slow, are solved. The 3D structure information of a sample can be quickly acquired and analyzed, and the acquired data has the characteristic of auto-registration. Moreover, molecular phenotype dyeing is performed on a sample slice of a part of interest to get the molecular phenotype information of the sample, and the molecular phenotype information can be registered into the acquired 3D structure information.

The described invention provides a system and method for clinical outcome tracking and analysis. The clinical outcome tracking and analysis comprises sorting, outcome tracking, quality of life metrics, toxicity to therapy and cost of care. The system and method includes receiving one or more parameters. Exemplary parameters for sorting include sex, age, ethnicity, comorbidities, tobacco use, source of insurance, medical record number, primary care physician, referring physician, hospital, approved service vendors, disease-specific clinical molecular phenotype, therapy intent, stage of therapy, biomarkers, and cost of care.

Methods and compositions to impute or predict genotype, haplotype, molecular phenotype, agronomic phenotypes, and/or coancestry are provided. Methods and compositions provided include using latent space to generate latent space representations or latent vectors that are independent of underlying genotypic or phenotypic data. The methods may include generating a universal latent space representation by encoding discrete or continuous variables derived from genotypic or phenotypic data into latent vectors through a machine learning-based encoder framework. Provided herein are universal methods of parametrically representing genotypic or phenotypic data obtained from one or more populations or sample sets to impute or predict a genotype or phenotype of interest.

The invention discloses an EpCAM/PSMA dual-antibody-based functionalized micro-fluidic chip as well as a preparation method and application thereof. The invention also discloses a method for capturingprostatic cancer CTCs by using the EpCAM/PSMA dual-antibody-based functionalized micro-fluidic chip as well as method for analyzing relevant molecular characteristic spectrum for the captured prostatic cancer CTCs. The relevant molecular phenotype is a prostatic cancer transfer relevant marker SChLAP1/PSA as well as targeting treatment response marker AR/PD-L1, so that a prostatic cancer CTCs molecular characteristic spectrum joint detection method and a detection kit can be constructed. The EpCAM/PSMA dual-antibody-based functionalized micro-fluidic chip is effective, high in specificity, high in sensitivity and high in accuracy, and also has clinical practical value, and the tetramolecular joint detection is used for the early warning of the transfer and reoccurrence and the curative effect evaluation in the prostatic cancer CTCs as well as improves the feasibility and credibility of the clinical use by virtue of the targeting treatment.

A system and method for analyzing a data store of de-identified patient data to generate one or more dynamic user interfaces usable to predict an expected response of a particular patient population or cohort when provided with a certain treatment. The automated analysis of patterns occurring in patient clinical, molecular, phenotypic, and response data, as facilitated by the various user interfaces, provides an efficient, intuitive way for clinicians to evaluate large data sets to aid in the potential discovery of insights of therapeutic significance.

A system and method for analyzing a data store of de-identified patient data to generate one or more dynamic user interfaces usable to predict an expected response of a particular patient population or cohort when provided with a certain treatment. The automated analysis of patterns occurring in patient clinical, molecular, phenotypic, and response data, as facilitated by the various user interfaces, provides an efficient, intuitive way for clinicians to evaluate large data sets to aid in the potential discovery of insights of therapeutic significance.

The invention provides a separation method for hepatic inherent and infiltrating macrophages. The separation method comprises the following steps of (1) establishing and identifying mouse allogeneicbone marrow transplantation model, wherein a surface marker of a mononuclear macrophage of a recipient mouse is CD45.2, and a surface marker of a mononuclear macrophage of a donor mouse is CD45.1; (2)observing and irradiating the influence on hepatic parenchymal cells and inherent macrophages with an IHC method and a flow cytometry; and (3) irradiating a mononuclear cell of a mouse liver in a transplantation group with primary isolation, and sorting the hepatic inherent and infiltrating macrophages with the flow cytometry according to the surface marker of the mononuclear macrophage of the donor mouse, and describing the quantities, distribution and phenotypes of the hepatic inherent and infiltrating macrophages. In the separation method provided by the invention, by removing the CD45.2 recipient mouse bone marrow derived macrophages by irradiation and supplementing and replacing bone marrow cells of the recipient mouse with CD45.1 donor mouse bone marrows, the bone marrow derived infiltrating macrophages and the bone marrow derived inherent macrophages have different molecular phenotypes and achieves the effect of accurately and efficiently separating different hepatic macrophages.

The invention discloses a kiwi berry natural heterozygote identification method, and relates to the fields of plant genetic resource evaluation and the biotechnology. The method concretely includes the following steps: 1, collecting natural heterozygous samples to be identified and hypothetical control parents; 2, carrying out genome heredity analysis on the sample by using a microsatellite molecule marker; 3, constructing the microsatellite molecule phenotype database of all the samples; 4, determining a true control parent by using multiple correspondence analysis of the molecular phenotype data; and 5, identifying the natural heterozygote based on the control parent. Compared with traditional kiwi berry natural heterozygote identification methods, the kiwi berry natural heterozygote identification method has the characteristics of simple molecular experimental process, fast and efficient analysis and identification flow, and the like; the method can overcome the problems of difficult kiwi berry pure and control sample determination, difficult processing of complex data of genome ploidy, and the like; and the method also can mitigate the influences of genetic coancestry on the heterozygote identification.

The present invention relates to a method for single-cell imaging mass spectrometry (MS) by correlating an optical image of a cell sample with an MS image. The method of the invention is in particular useful in research to test concomitantly optical and molecular phenotypes at a single-cell resolution.

The invention relates to the technical field of biomedical engineering, and provides a human gallbladder stem cell acquisition and long-term in-vitro culture method. The method comprises a human gallbladder stem cell acquisition method and a human gallbladder stem cell long-term in-vitro culture method. A primary culture medium and a cell expansion culture medium with clear chemical components areprovided. By adopting the two culture media, selective amplification of the gallbladder stem cells in human gallbladder tissues is realized, the cells can be continuously cultured in vitro for more than 100 days under the condition, and a stable liver stem cell related molecular phenotype is maintained; after induced differentiation, the cells have partial liver functions, including ingestion oflow-density lipoprotein, synthesis of fat and storage of glycogen. Therefore, the gallbladder stem cells obtained by the method can be used as seed cells for cell therapy of liver failure diseases, and can be used for drug screening and preparation of tissue engineering liver and artificial liver.

The invention provides an in-vitro induction and long-term culture system, an induced culture method and application of forebrain neural stem cells. The in-vitro induction and long-term culture system comprises a basal culture medium, as well as an induced differentiation factor and an in-vitro culture factor which are combined with the basal culture medium for use, wherein the basal culture medium comprises a DMEM/F12 liquid basal culture medium, a 0-5*B27 additive, a 0-5*N2 additive, 1% penicillin/streptomycin and 0.01-500 mu g/mL 2-phosphoric acid- vitamin C; the induced differentiation factor comprises 0.01-500 mu M of a TGF[beta] inhibitor, 0.01-10000 mu M of a BMP inhibitor and 0.01-50 mu M of a Porcupine inhibitor; and the in-vitro culture factor comprises 0.01-10000 nM of an Src kinase inhibitor, 0.01-500 mu M of a TGF[beta] inhibitor, 0.01-50 mu M of a GSK3 inhibitor, 0.01-500 ng/mL of an EGF family growth factor and 0.01-500 ng/mL of an FGF family growth factor. By using the culture system, the pluripotent stem cells can be induced in vitro to be differentiated into the forebrain neural stem cells and cultured in vitro for a long time, and the stable molecular phenotype and differentiation potential of the forebrain neural stem cells are maintained.

Heritable pathogenic variants in the mismatch repair (MMR) pathway, also known as Lynch Syndrome (LS), can lead to the development of colon cancer and other cancers. Following mismatch, a complex of proteins consisting of MLH1, MSH2, MSH6 and PMS2 translocate into the nucleus to signal recruitment of repair mechanisms. Flow cytometry-based, functional variant assays (FVAs), were developed to determine whether variants in these MMR repair genes and/or other related genes would augment the nuclear translocation of MLH1 and MSH2 and downstream nuclear phosphorylation of ATM and ATR in response to DNA mismatches. Each assay distinguished pathogenic variants in MMR repair genes (MLH1, MSH2, PMS2 and MSH6) from benign controls. The combination of multiple assays provided robust separation between heterozygous pathogenic variant carriers and benign controls. The ability to produce distinct molecular phenotypes by these assays suggest FVA assays of MMR pathways could be used to identify LS and associated risk of colon and other cancers and could act as an adjunct to MMR gene sequencing panels in categorizing variants.